Alnylam Pharma (ALNY) Misses Q2 EPS by 10c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $288.18 +0.62%
EPS Growth %: +409.4%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +409.4%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($0.85), $0.10 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $8.69 million versus the consensus estimate of $12.64 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
- Cerebras Systems posts 94% revenue jump, announces OpenAI deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
